Skip to product information
1 of 1

Mouse anti-Human CD36 Antibody (S-R617)

Mouse anti-Human CD36 Antibody (S-R617)

Catalog Number: S0B5094 Application: FCM Reactivity: Human Conjugation: Unconjugated Brand: Starter
Price:
Regular price $100.00 USD
Regular price Sale price $100.00 USD
Size:
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Mouse
Antigen CD36
Synonyms Platelet glycoprotein 4; Fatty acid translocase (FAT); Glycoprotein IIIb (GPIIIB); Leukocyte differentiation antigen CD36; PAS IV; PAS-4; More alternative names; GP3B; GP4;
Location Cell membrane
Accession P16671
Clone Number S-R617
Antibody Type Mouse mAb
Isotype IgG1,k
Application FCM
Reactivity Hu
Positive Sample human peripheral blood
Purification Protein G
Concentration 2 mg/ml
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS pH7.4

Stability & Storage 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied.

Dilution


application dilution species
FCM 1:2000 Hu

Background

CD36, also known as cluster of differentiation 36, is an 88-kDa integral membrane glycoprotein expressed on various cell types, including platelets, monocytes, adipocytes, hepatocytes, myocytes, and microvascular endothelial cells. It functions as a class B scavenger receptor that binds multiple ligands such as long-chain fatty acids, oxidized low-density lipoprotein (oxLDL), collagen, thrombospondin, and anionic phospholipids. CD36 plays a crucial role in lipid metabolism, facilitating the uptake of fatty acids and contributing to lipid accumulation under excessive fat supply. In the context of cancer, CD36 is overexpressed in several types of tumors, including breast, brain, and ovarian cancers, where it promotes tumor growth, migration, and metastasis by supporting lipid metabolism and metabolic reprogramming. Additionally, CD36 is involved in immune responses and drug resistance in cancer cells. Its dysregulated expression is associated with poor prognosis in various cancers. Recent research has focused on developing CD36-targeted therapies, such as small-molecule inhibitors and antibodies, to address its role in cancer progression.

Picture

FC

Flow cytometric analysis of human peripheral blood labelling Human CD36 antibody at 1/2000 (0.1 μg) dilution/ (Right panel) compared with a Mouse IgG1, κ Isotype Control / (Left panel). Goat Anti-Mouse IgG Alexa Fluor® 647 was used as the secondary antibody. Then cells were stained with HLA/DR - Brilliant Violet 605™ Antibody separately.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)